Issues in Multicenter Clinical Trials

Clinical trials at the late stages are expensive and ineffective.Simple assumptions result in a trial that is underpowered,not properly accounting for variation.The drug supply chain can be quite wasteful.Independent design choices are made for interrelated elements.

Interacting Design Factors

  • Recruitment of patients
  • How many facilities are there, how long is the wait, etc.
  • Randomization
  • Statistical simulation
  • The number of patients, ideal analysis model, etc.
  • Patient abandonment
  • Drug supply

    Related Conference of Issues in Multicenter Clinical Trials

    April 04-05, 2024

    17th European Biosimilars Congress

    Madrid, Spain
    April 11-12, 2024

    5th Annual Congress on Antibiotics and Bacterial Infections

    Amsterdam, Netherlands
    May 09-10, 2024

    4th Global Summit on Pharmaceutical Research

    Barcelona, Spain
    May 16-17, 2024

    18th World Drug Delivery Summit

    Rome, Italy
    May 30-31, 2024

    9th Pharmaceutical Chemistry Conference

    Paris, France
    July 25-26, 2024

    34th Annual European Pharma Congress

    Frankfurt, Germany
    September 11-12, 2024

    9th International Conference on Future Pharma and Innovations

    Amsterdam, Netherlands
    September 25-26, 2024

    4th World Congress on Rare Diseases & Orphan Drugs

    Paris, France
    November 26-27, 2024

    3rd World Conference on Pharma Industry and Medical Devices

    Zurich, Switzerland
    November 26-27, 2024

    3rd World Congress on Precision and Personalized Medicine

    Zurich, Switzerland
    November 28-29, 2024

    39th World Congress on Pharmacology and Therapeutics

    Paris, France
    November 28-29, 2024

    12th International Conference on Clinical Trials

    Vancouver, Canada
    December 05-06, 2024

    17th World Drug Delivery Summit

    Dubai, UAE

    Issues in Multicenter Clinical Trials Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in